ABSINTHIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H40O6
Molecular Weight	496.635
Optical Activity	UNSPECIFIED
Defined Stereocenters	14 / 14
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1[C@@H]2CC[C@](C)(O)[C@@H]3[C@H]4[C@H]5C=C(C)[C@@]6([C@H]7OC(=O)[C@@H](C)[C@@H]7CC[C@](C)(O)[C@H]56)[C@H]4C(C)=C3[C@H]2OC1=O

InChI

InChIKey=PZHWYURJZAPXAN-ILOFNVQHSA-N

InChI=1S/C30H40O6/c1-12-11-18-20-21(30(12)24(18)29(6,34)10-8-17-14(3)27(32)36-25(17)30)15(4)19-22(20)28(5,33)9-7-16-13(2)26(31)35-23(16)19/h11,13-14,16-18,20-25,33-34H,7-10H2,1-6H3/t13-,14-,16-,17-,18+,20-,21-,22-,23-,24-,25-,28-,29-,30+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26495959 | http://foodb.ca/compounds/FDB014471

Absinthin is a triterpene, extracted from a Chinese herb, with anti-inflammatory properties.Absinthin is a naturally produced molecule from the plant Artemisia absinthium (Wormwood). It constitutes one of the most bitter chemical agents responsible for Absinthe's distinct taste. Absinthin attenuates LPS-induced ALI through MIP-1α-mediated inflammatory cell infiltration. Absinthin is a promising novel therapeutic candidate for the treatment of ALI.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Neutrophil collagenase 2 Target ID: O70138 Gene ID: 17394.0 Gene Symbol: Mmp8 Target Organism: Mus musculus (Mouse) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26495959	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute lung injury 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26495959	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Ultraviolet light absorption of an ophthalmic formulation with Aloe extracts.	2009-09	19831035
Women's health among the Chumash.	2006-03	16550233
Absinthe--a review.	2006	16891209
Total synthesis of absinthin.	2005-01-12	15631427

Patents

Sample Use Guides

In Vivo Use Guide

Mice were treated with various concentrations (20 mg/kg, 40 mg/kg, and 80mg/kg) of absinthin, and lipopolysaccharide (LPS) to induce ALI.

Route of Administration: Unknown

In Vitro Use Guide

RAW264.7 macrophages were treated with absinthin (either 10 ug/ml, 50 ug/ml, or 100 ug/ml) plus lipopolysaccharide (LPS) (1 ug/ml), or with LPS alone, for 24 h.

Name

Type

Language

ABSINTHIN

Common Name

English

NSC-407315

Preferred Name

English

ABSYNTHIN

Common Name

English

CHIEF BITTER PRINCIPLE OF ARTEMISIA ABSINTHIUM

Common Name

English

(+)-ABSINTHIN

Common Name

English

ABSINTHIN [MI]

Common Name

English

ABSINTHIIN

Common Name

English

Code System Code Type Description

PUBCHEM

442138